Leap Therapeutics, Inc. announced changes to the company's Executive Leadership Team. All changes to the Board of Directors are effective immediately. Other management changes will take effect April 1, 2020, and include the following: Christopher K. Mirabelli, Ph.D., will be stepping down from his role as President and Chief Executive Officer.

Dr. Mirabelli will continue to serve as the Chairman of Leap's Board of Directors and provide ongoing leadership and guidance around the Company's biomarker and research efforts; Douglas E. Onsi, Leap's Chief Financial Officer, is being named President and Chief Executive Officer, while maintaining his current role. Mr. Onsi will also serve as a member of the Board of Directors; John Littlechild will be stepping down from Leap's Board of Directors; Cynthia Sirard, M.D., Vice President, Clinical Research & Development, has been promoted to Chief Medical Officer; Mark O'Mahony, Vice President of Manufacturing, has been promoted to Chief Manufacturing Officer. Mr. O'Mahony has been Vice President of Manufacturing at Leap since 2011.

Dr. Sirard has been Vice President of Clinical Research and Development at Leap since 2012.